Recent Updates
Recently added Catalysts
CPIX

Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011

Key Takeaway: NASHVILLE, Tenn., Feb. 17, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release 2010 financial results after the market closes on Tuesday, March 8, 2011. A conference call and live Internet webcast will be held on Tuesday, March

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+159%
120-day peak, hindsight
Typical move
11.7%
average across 5 past catalysts
Lead asset
Ifetroban
Phase 2 · Hepatorenal Syndrome

Full Press Release Details

NASHVILLE, Tenn., Feb. 17, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release 2010 financial results after the market closes on Tuesday, March 8, 2011. A conference call and live Internet webcast will be held on Tuesday, March 8, 2011 at 5:00 p.m. Eastern Time to discuss the results.
To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers). The Conference ID for the rebroadcast is 45026812. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.
Last updated: Feb 17, 2011